References

  1. VAGIFEM® patient package insert. Princeton, NJ. Novo Nordisk Inc., 2003.
  2. US Department of Health and Human Services. Facts About Postmenopausal Hormone Therapy. Washington, DC. US Department of Health and Human Services, 2002.
  3. Menopause Guidebook. Cleveland, Oh. The North American Menopause Society, 2003.
  4. Mishell DR. Menopause: Physiology and Pharmacology. Chicago. Year Book Medical Publishers, 1987.
  5. Atrophic vaginitis. Healthgate/Brigham and Women’s Hospital website. http://healthgate.partners.org/browsing/browseContent.asp?fileName=100094.xml&title=Atrophic%20Vaginitis. Accessed August 20, 2007.
  6. Beckmann CRB, Ling FW, Laube DW, et al. “Menopause.” In Marquardt N, ed. Obstetrics and Gynecology. 4th ed. Baltimore, Md. Lippincott Williams & Wilkins, 1998:482-493.
  7. Castelo-Branco C, Rostro F. C. Castelo-Branco, Institut Clínic de Ginecologia Obstetrícia i Neonatologia, Hospital Clínic, Universidad de Barcelona. Treatment of atrophic vaginitis. Therapy. 2007;vol. 4(3), 349-353.
  8. VAGIFEM® prescribing information. Princeton, NJ. Novo Nordisk Inc., 2003.
  9. The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy: 2007 position statement of The North American Menopause Society. The Journal of The North American Menopause Society. 2007;vol 14(3): 355-371.
Important Safety Information